A. Buzdar

Publications777
h-index113
Citations55,473
Highly Influential Citations1,408
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Hortobagyi
  • 1,771 Publications • 113,974 Citations
  • M. Dowsett
  • 1,154 Publications • 93,181 Citations
  • J. Ingle
  • 641 Publications • 59,245 Citations
  • G. Blumenschein
  • 518 Publications • 31,144 Citations
  • Publications
  • Influence
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
View on Elsevier
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
TLDR
Residual cancer burden was calculated as a continuous index combining pathologic measurements of primary tumor and nodal metastases and was a significant predictor of distant relapse-free survival (DRFS) in multivariate Cox regression analyses.
View on PubMed
Breast carcinoma in men
TLDR
The goals of the current study were to fill in the major gaps in knowledge regarding the incidence, presenting characteristics, prognostic factors, and survival rates of male breast carcinoma and to determine how Breast carcinoma differs between men and women.
View on Wiley
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
TLDR
A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value.
View on PubMed
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
TLDR
Neoadjuvant chemotherapy has the capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery and patients with LABC who have a pCR in the breastand axillary nodes have a significantly improved disease-free survival rate.
View on PubMed
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
View on PubMed
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health…
TLDR
The amount of prognostic information contained in four widely performed IHC assays is similar to that in the GHI-RS, which confirmed earlier reports that the mRNA-based, 21-gene Genomic Health recurrence score provided additional prognosis information regarding distant recurrence beyond that obtained from classical clinicopathologic factors.
View on PubMed
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth…
TLDR
Adding trastuzumab to chemotherapy, as used in this trial, significantly increased pathologic complete response (pCR) rate without clinical congestive heart failure, according to the small sample size.
View on PubMed
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
View on PubMed
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
TLDR
Capecitabine is an active drug in the treatment of paclitaxel-refractory metastatic metastatic breast cancer and has a favorable toxicity profile with the added advantage of being an oral drug administered at home.
View on PubMed
...
...